At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 82 enrolled
Drug / intervention
carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye
In Brief
A Phase 4 clinical trial evaluating carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD) and sodium hyaluronate 0.18% (VISMED® Multi) for Dry Eye Syndromes and Keratoconjunctivitis Sicca. Completed, enrolled 82 participants across 1 site.
Detailed Summary
This study will evaluate the safety and efficacy of OPTIVE® MD for ocular surface integrity in symptomatic dry eye condition in absence of obvious eye-lid inflammation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Syndromes, Keratoconjunctivitis Sicca
CountriesFrance
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2009
Enrollment StartNov 2009
Primary CompletionJul 2010
Study CompletionSep 2010
TodayJul 2026
First PostedOct 1, 2009
Enrollment StartNov 1, 2009
Primary CompletionJul 1, 2010
Study CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 16.8 years ago
Interventions
carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)drug
One drop in each eye three to six times daily, as needed
sodium hyaluronate 0.18% (VISMED® Multi)drug
One drop in each eye three to six times daily, as needed